Drug profile · INN
tenofovir disoproxil fumarate
TENOFOVIR DISOPROXIL FUMARATE
tenofovir disoproxil fumarate (TENOFOVIR DISOPROXIL FUMARATE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — tenofovir disoproxil fumarate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
tenofovir disoproxil fumarate (TENOFOVIR DISOPROXIL FUMARATE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Primary target: Human immunodeficiency virus type 1 reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tenofovir disoproxil fumarate?
tenofovir disoproxil fumarate (TENOFOVIR DISOPROXIL FUMARATE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tenofovir disoproxil fumarate?
TENOFOVIR DISOPROXIL FUMARATE is a marketed brand name for tenofovir disoproxil fumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tenofovir disoproxil fumarate?
tenofovir disoproxil fumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.